Clinical Trial Update: A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of acalabrutinib plus vistusertib in relapsed/refractory B-cell malignancies (DLBCL and Richter syndrome) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Richter Transformation

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• vistusertib (vistusertib)

Snippet

Sponsor: Acerta Pharma BV | Conditions: DLBCL, Richter Syndrome | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-01-06